Mitochondrial Microproteins: Unexplored Potential in Lung Disease
Background
Mitochondrial-derived microproteins (MDPs) are bioactive peptides encoded by small open reading frames within mitochondrial DNA. These microproteins have been implicated in various disease states, exhibiting actions within mitochondria, the nucleus, and the extracellular space. However, most research has focused on MOTS-c and Humanin in tissues with high mitochondrial density like the heart, skeletal muscle, and brain, or in conditions such as Alzheimer's, cancer, and cardiovascular disease, leaving a significant knowledge gap regarding their role in lung homeostasis and disease.
Results
The review confirmed that MDPs are consistently altered in numerous disease states, demonstrating diverse actions across mitochondrial, nuclear, and extracellular compartments. While their significance is well-established in tissues like the heart and brain, and in age-related conditions, the authors found a substantial and critical knowledge gap regarding MDPs' specific roles in lung homeostasis and various pulmonary diseases. The most critical finding is the pronounced lack of dedicated research on MDPs in conditions such as acute lung injury, chronic obstructive pulmonary disease (COPD), allergic asthma, and pulmonary fibrosis, despite their increasingly recognized importance in other non-pulmonary pathologies.
Why It Matters
This review highlights a significant untapped area of research with profound implications for understanding and treating lung diseases. Given the established roles of MDPs in other complex diseases, their investigation in pulmonary contexts could uncover novel diagnostic biomarkers and therapeutic targets. The authors strongly advocate for increased research to explore MDPs' mechanistic roles and their potential to inform future clinical strategies, potentially leading to new treatments for debilitating lung conditions like COPD and pulmonary fibrosis.